R

ise and shine, everyone, another busy day is on the way. Our harried routine is already underway, of course, although we are helped along this morning by a shiny sun and the soothing, rhythmic snores of the official mascots. Such a life. So, time to get cracking, as they say — hoist a cup of stimulation. As always, here are some tidbits. Hope you conquer the world today and please do pass along any tips, secrets and unredacted documents.

In statehouses across the country, and in Congress, Alkermes is pushing Vivitrol — a monthly shot used to treat opioid addiction — while contributing to misconceptions and stigma about other medications used to treat the problem, NPR informs us. Alkermes is using policy to promote its drug and, in some cases, hamper access to medications that can help and, in doing so, is looking to turn its drug into a blockbuster.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Vivitrol costs $15,000/year. Oral naltrexone costs $40/year, which would probably make Vivitrol a prior authorization Tier 5 drug. Good luck on that one.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy